Interesting read. Would have thought we have made more progress on the daptomycin and Propofol fronts. Seems like a lot of the business development discussion terminology has been dropped. The Animal health has all but died. I mean honestly why the heck are they referring to multiple companies still analysing this.
The cannabis sector seems the focus for short term cash.
Why are they able to suggest a timeline for cannabis side of the business but not the other parts?
I hope we get more from the webiner.
Ann: Avecho Investor Update, page-3
-
- There are more pages in this discussion • 74 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.508M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.3¢ | 0.2¢ | $3.607K | 1.445M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 59 | 102396408 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 21041400 | 12 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| AVE (ASX) Chart |